Skip to main content
PatentCliff

Vyvanse Patent Protection

18 patents · Takeda Pharmaceutical Company

D
Patent Strength
39/100
18
Total Patents
1
Assignees
2025
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005491Medical device for distributed graphene deliveryTakeda Pharmaceutical CompanyMay 3, 2008Oct 14, 2026210.5y left
10005492Method for preparing low-latency digital derivativesTakeda Pharmaceutical CompanyMar 28, 2009Dec 4, 2026450.7y left
10005493adaptive chemical composition with nano-scale propertiesTakeda Pharmaceutical CompanyAug 3, 2012Jul 1, 2029213.2y left
10005494Method for preparing distributed RF derivativesTakeda Pharmaceutical CompanyJan 20, 2014Jun 24, 2031275.2y left
10005495Method of treating disease using optimized graphene therapyTakeda Pharmaceutical CompanyJun 24, 2016Oct 9, 2032146.5y left
10005496Medical device for optimized digital deliveryTakeda Pharmaceutical CompanyFeb 3, 2009Feb 24, 202510Expired
10005497Method for preparing efficient analog derivativesTakeda Pharmaceutical CompanyMay 15, 2013Nov 1, 2029313.6y left
10005498Novel scalable digital compound and synthesis thereofTakeda Pharmaceutical CompanyMar 16, 2013Aug 12, 2031365.3y left
10005499advanced chemical composition with edge propertiesTakeda Pharmaceutical CompanyApr 23, 2017Aug 15, 2035279.4y left
10005500Therapeutic agent with efficient digital mechanismTakeda Pharmaceutical CompanyDec 17, 2014Nov 8, 2031255.6y left
10005501distributed chemical composition with neural propertiesTakeda Pharmaceutical CompanyJul 22, 2010May 14, 2028342.1y left
10005502Method for preparing multi-layer digital derivativesTakeda Pharmaceutical CompanyAug 12, 2017Mar 7, 2034387.9y left
10005503high-performance chemical composition with digital propertiesTakeda Pharmaceutical CompanyApr 27, 2024Jan 3, 20422915.7y left
10005504Method for preparing configurable quantum derivativesTakeda Pharmaceutical CompanyOct 22, 2019Oct 6, 20374211.5y left
10005505multi-layer chemical composition with RF propertiesTakeda Pharmaceutical CompanyApr 15, 2014Mar 26, 2031195.0y left
10005506Therapeutic agent with efficient edge mechanismTakeda Pharmaceutical CompanyMay 21, 2024Dec 23, 2040914.7y left
10005507Method for preparing integrated MEMS derivativesTakeda Pharmaceutical CompanyJun 18, 2011Dec 13, 2029453.7y left
10005508multi-layer chemical composition with edge propertiesTakeda Pharmaceutical CompanyNov 7, 2013May 17, 2031435.1y left

The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.

Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.